Yes, this is an interesting dilemma and set of questions that it poses. Post combo HIV approval and pre-cancer approval, does HIV license partner get the benefit of off-label revenues?

My guess they would if no cancer license agreement is in place and even if one is, I'm not sure how they would be able to control this easily (haven't researched, but others previously noted that different names can be used)? IMO this provides any potential license partners to act sooner rather than later.....or the HIV partner to add the cancer pipeline also?

Personally, if human results confirm pre-clinical results, I expect BTD and AA to have cancer approval shortly after combo (sometime in 2020). As far as off-label insurance payments, someone (plavac I believe) noted that insurance companies largely follow NCCN recommendations.